Skip to main content
SpringerLink
Log in

Intravenous Immunoglobulin Adjunctive Therapy in Patients with Streptococcal Toxic Shock Syndrome and Necrotizing Fasciitis

  • Chapter
Cytokines and Chemokines in Infectious Diseases Handbook

Part of the book series: Infectious Disease ((ID))

  • 169 Accesses

Abstract

Streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis caused by group A streptococcus (GAS) are rapidly-progressive invasive diseases that are associated with high mortality rates, ranging from 30% to 80% despite prompt antibiotic therapy and surgical debridement (1). Intense research in the field of GAS pathogenesis has unraveled complex host-pathogen interplay and provided an impetus for the design of novel therapeutic strategies to attenuate or prevent these diseases. One of the more promising therapeutic strategies is the intravenous administration of polyspecific immunoglobulin (IVIG) to patients with severe invasive GAS infections. In this chapter, we will review the mechanistic actions and use of IVIG as adjunctive therapy for severe invasive GAS infections. In doing so, we will also highlight epidemiological and pathogenic aspects of invasive GAS infections and show how IVIG acts, in part, by attenuating the inflammatory cytokine cascade in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Low, D.E., Schwartz, B., and McGeer, A. (1998) The reemergance of severe group A streptococcal disease: an evolutionary perspective, in Emerging Pathogens, Vol. 7, ASM Press, Washington, DC.

    Google Scholar 

  2. Katz, A.R. and Morens, D.M. (1992) Severe streptococcal infections in historical perspective. Clin. Infect. Dis. 14, 298–307.

    PubMed  CAS  Google Scholar 

  3. Descamps, V., Aitken, J., and Lee, M.G. (1994) Hippocrates on necrotising fasciitis. Lancet 344, 556.

    PubMed  CAS  Google Scholar 

  4. Quinn, R.W. (1982) Epidemiology of group A streptococcal infections—their changing frequency and severity. Yale J. Biol. Med. 55, 265–270.

    PubMed  CAS  Google Scholar 

  5. Kaplan, E. (1993) Global assessment of rheumatic fever and rheumatic heart disease at the close of the century. The influences and dynamics of population and pathogens: a failure to realize prevention? (The T. Duckettt Jones Memorial Lecture). Circulation 88, 1964–1972.

    PubMed  CAS  Google Scholar 

  6. Kaplan, E.L. (1996) Recent epidemiology of group A streptococcal infections in North America and abroad: an overview. Paediatrics 97, 945–948.

    CAS  Google Scholar 

  7. Keefer, C.S., Inglefinger, F.J., and Spink, W.W. (1937) Significance of hemolytic streptococci bacteraemia: a study of two hundred and forty six patients. Arch. Intern. Med. 60, 1084–1097.

    Google Scholar 

  8. Hable, K.A., Horstmeirer, C., Wold, A.D., and Washington, J.A. (1973) Group A p-hemolytic streptococcemia: bacte-riologic and clinical study of 44 cases. Mayo Clin. Proc. 48, 336–339.

    PubMed  CAS  Google Scholar 

  9. Duma, R.J., Weinberg, A.N., Medrek, T.F., and Kunz, L.J. (1969) Streptococcal infections: a bacteriologic and clinical study of streptococcal bacteremia. Medicine 48, 87–127.

    Google Scholar 

  10. Goepel, J.R., Richards, D.G., Harris, D.M., and Henry, L. (1980) Fulminant Streptococcus pyogenes infection. Br. Med. J. 281, 1412.

    PubMed  CAS  Google Scholar 

  11. Gaworzewska, E. and Colman, G. (1988) Changes in the pattern of infection caused by Streptococcus pyogenes. Epidemiol. Infect. 100, 257–269.

    PubMed  CAS  Google Scholar 

  12. Hoge, C.W., Schwartz, B., Talkington, D.F., Breiman, R., MacNeill, E.M., and Englender, S.J. (1993) The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA 269, 384–389.

    PubMed  CAS  Google Scholar 

  13. Cone, L.A., Woodard, D.R., Schlievert, P.M., and Tomory, G.S. (1987) Clinical and bacteriological observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N. Engl. J. Med. 317, 146–149.

    PubMed  CAS  Google Scholar 

  14. Martin, P.R. and Hoiby, E.A. (1990) Streptococcal serogroup A epidemic in Norway 1987–1988. Scand. J. Infect. Dis. 22,421–429.

    PubMed  CAS  Google Scholar 

  15. Schwartz, B., Facklam, R.R., and Breiman, R.F. (1990) Changing epidemiology of group A streptococcal infection in the USA. Lancet 336, 1167–1171.

    PubMed  CAS  Google Scholar 

  16. Stromberg, A., Romanus, V., and Burman, L.G. (1991) Outbreak of group A streptococcal bacteremia in Sweden: an epidemiological and clinical study. J. Infect. Dis. 164, 595–598.

    PubMed  CAS  Google Scholar 

  17. The Working Group on Severe Streptococcal Infections (1993) Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA 269, 390–391.

    Google Scholar 

  18. Chelsom, J., Halstensen, A., Haga, T., and Hoiby, A. (1994) Necrotizing fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 344, 1111–1115.

    PubMed  CAS  Google Scholar 

  19. Demers, B., Simor, A.E., Vellend, H., Schlievert, P.M., Byrne, S., Jamieson, F., et al. (1993) Severe invasive group A streptococcal infections in Ontario, Canada: 1987–1991. Clin. Infect. Dis. 16, 792–800.

    PubMed  CAS  Google Scholar 

  20. Kaul, R., McGeer, A., Low, D.E., Green, K., Schwartz, B., Ontario group A Streptococcal Study Group, and Simor, E. (1997) Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am. J. Med. 103, 18–24.

    PubMed  CAS  Google Scholar 

  21. Stevens, D.L., Tanner, M.H., Winship, J., Swarts, R., Ries, K.M., Schlievert, P.M., et al. (1989) Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. 321, 1–7.

    PubMed  CAS  Google Scholar 

  22. Colman, G., Tanna, A., Efstratiou, A., and Gaworzewska, E. (1993) The serotypes of Streptococcus pyogenes present in Britain during 1980–1990 and their association with disease. J. Med. Microbiol. 39, 165–178.

    PubMed  CAS  Google Scholar 

  23. Kaul, R., McGeer, A., Norrby-Teglund, A., Kotb, M., Schwartz, B., O’Rourke, K., et al., and The Canadian Streptococcal Study Group (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome — a comparative observational study. Clin. Infect. Dis. 28, 800–807.

    PubMed  CAS  Google Scholar 

  24. Cockerill, F.R., 3rd., MacDonald, K.L., Thompson, R.L., Roberson, F., Kohner, P.C., Besser-Wiekm, J., et al. (1997) An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 277, 38–43.

    PubMed  Google Scholar 

  25. Holm, S.E., Norrby, A., Bergholm, A.-M., and Norgren, M. (1992) Aspects of the pathogenesis in serious group A streptococcal infections in Sweden 1988–1989. J. Infect. Dis. 166, 31–37.

    PubMed  CAS  Google Scholar 

  26. Eriksson, B.K., Andersson, J., Holm, S.E., and Norgren, M. (1999) Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J. Infect. Dis. 180, 410–418.

    PubMed  CAS  Google Scholar 

  27. Kiska, D.L., Thiede, B., Caracciolo, J., Jordan, M., Johnson, D., Kaplan, E.L., et al. (1997) Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J. Infect. Dis. 176, 992–1000.

    PubMed  CAS  Google Scholar 

  28. Nakashima, K., Ichiyama, S., Iinuma, Y., Hasgawa, Y., Ohta, M., Ooe, K., et al. (1997) A clinical and bacteriologic investigation of invasive streptococcal infections in Japan on the basis of serotypes, toxin production, and genomic DNA fingerprints. Clin. Infect. Dis. 25, 260–266.

    PubMed  CAS  Google Scholar 

  29. Upton, M., Carter, P.E., Orange, G., and Pennington, T.H. (1996) Genetic heterogeneity of M type 3 group A streptococci causing severe infections in Tayside, Scotland. J. Clin. Microbiol 34, 196–198.

    PubMed  CAS  Google Scholar 

  30. Svensson, N., Oberg, S., Henriques, B., Holm, S., Kallenius, G., Romanus, V. et al. (2000) Invasive group A streptococcal infections in Sweden in 1994 and 1995: epidemiology and clinical spectrum. Scand. J. Infect. Dis. 32,609–614.

    PubMed  CAS  Google Scholar 

  31. McGeer, A., Willey, B., Schwartz, B., Green, K., Bernston, A., Trpeski, L., et al., Group A Streptococcal Study and Low D.E. (1998) Epidemiology of invasive GAS disease due to M3 serotypes in Ontario, Canada, in Abstracts of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM, Washington, DC.

    Google Scholar 

  32. Cunningham, M.W. (2000) Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13, 470–511.

    PubMed  CAS  Google Scholar 

  33. Boyle, M.D. (1995) Variation of multifunctional surface binding proteins—a virulence strategy for group A streptococci? J. Theor. Biol. 21, 415–426.

    Google Scholar 

  34. Fischetti, V.A. (1989) Streptococcal M protein: molecular design and biological behavior. Clin. Microbiol. Rev. 2, 285–314.

    PubMed  CAS  Google Scholar 

  35. Norrby-Teglund, A. and Kotb, M. (2000) Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J. Med. Microbiol. 49, 849–852.

    PubMed  CAS  Google Scholar 

  36. Kotb, M. (1998) Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Curr. Opin. Microbiol. 1, 56–65.

    PubMed  CAS  Google Scholar 

  37. Kotb, M. (1995) Bacterial pyrogenic exotoxins as superantigens. Clin. Microbiol. Rev. 8, 411–426.

    PubMed  CAS  Google Scholar 

  38. Proft, T., Louise Moffatt, S., Berkahn, C.J., and Fraser, J.D. (1999) Identification and characterization of novel superantigens from Streptococcus pyogenes. J. Exp. Med. 189, 89–102.

    PubMed  CAS  Google Scholar 

  39. Mollick, J.A., Miller, G.G., Musser, J., Cook, R.G., Grossman, D., and Rich, R.R. (1993) A novel superantigen isolated from pathogenic strains of S. pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J. Clin. Invest. 92,710–719.

    PubMed  CAS  Google Scholar 

  40. Kamezawa, Y., Nakahara, T., Nakano, S., Abe, Y., Nozaki-Renard, J., and Isono, T. (1997) Streptococcal mitogenic exotoxin Z, a novel acidic superantigenic toxin produced by a Tl strain of Streptococcus pyogenes. Infect. Immun. 65, 3828–3833.

    PubMed  CAS  Google Scholar 

  41. Reda, K.B., Kapur, V., Goela, D., Lamphear, J.G., Musser, J.M., and Rich, R.R. (1996) Phylogenetic distribution of streptococcal superantigen SSA allelic variants provides evidence for horizontal transfer of ssa within Streptococcus pyogenes. Infect. Immun. 64, 1161–1165.

    PubMed  CAS  Google Scholar 

  42. Lancefield, R.C. (1962) Current knowledge of type-specific M antigen of group A streptococci. J. Immunol. 89, 307–313.

    PubMed  CAS  Google Scholar 

  43. Facklam, R., Beall, B., Efstratiou, A., Fischetti, V., Johnson, D., Kaplan, E., et al. (1999) emm typing and validation of provisional M types for group A streptococci. Emerg. Infect. Dis. 5, 247–253.

    PubMed  CAS  Google Scholar 

  44. Basma, H., Norrby-Teglund, A., McGeer, A., Low, D.E., El-Ahmedy, O., Dale, J.B., et al. (1998) Opsonic antibodies to the surface M protein, present in pooled normal immunoglobulins (IVIG), may contribute to its clinical efficacy in severe invasive group A streptococcal infections. Infect. Immun. 66, 2279–2283.

    PubMed  CAS  Google Scholar 

  45. Basma, H., Norrby-Teglund, A., Guedez, Y., McGeer, A., Low, D.E., El-Ahmedy, O., et al. (1999) Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect. Immun 67, 1871–1877.

    PubMed  CAS  Google Scholar 

  46. Mascini, E.M., Jansze, M., Schellekens, J.F., Musser, J.M., Faber, J.A., Verhoef-Verhage, L.A., et al. (2000) Invasive group A streptococcal disease in the Netherlands: evidence for a protective role of anti-exotoxin A antibodies. J. Infect. Dis. 181,631–638.

    PubMed  CAS  Google Scholar 

  47. Norrby-Teglund, A., Pauksens, K., Holm, S.E., and Norgren, M. (1994) Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J. Infect. Dis. 170, 585–591.

    PubMed  CAS  Google Scholar 

  48. Stevens, D.L., Gibbons, A.E., Bergstrom, R., and Winn, V. (1988) The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158, 23–28.

    PubMed  CAS  Google Scholar 

  49. Stevens, D.L., Yan, S., and Bryant, A.E. (1993) Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J. Infect. Dis. 167, 1401–1405.

    PubMed  CAS  Google Scholar 

  50. Hook, E.W., Horton, C.A., and Schaberg, D.R. (1983) Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 249, 1055–1057.

    PubMed  Google Scholar 

  51. Davies, D.H., McGeer, A., Schwartz, B., Green, K., Cann, D., Simor, A.E., et al., and The Ontario Group A Streptococcal Study Group (1996) Invasive group A streptococcal infections in Ontario, Canada. N. Engl. J. Med. 135, 547–554.

    Google Scholar 

  52. Bisno, A.L. and Stevens, D.L. (1996) Streptococcal infections of skin and soft tissues. N. Engl. J. Med. 334, 240–245.

    PubMed  CAS  Google Scholar 

  53. Stevens, D.L. (1999) The flesh-eating bacterium: what’s next? J. Infect. Dis. 179(Suppl. 2), S366-S374.

    PubMed  Google Scholar 

  54. Muller, M.P., McGeer, A., Low, D.E., and Ontario Group A Streptococcal Study (2001) Successful outcome in six patients treated conservatively for suspected necrotizing fasciitis (NF) due to group A streptococccus (GAS), in Abstracts of 41 st Inter science Conference on Antimicrobial Agents and Chemotherapy, ASM, Washington, DC.

    Google Scholar 

  55. Brown, D.R., Davis, N.L., Lepawsky, M., Cunningham, J., and Kortbeek, J. (1994) A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am. J. Surg. 167, 485–489.

    PubMed  CAS  Google Scholar 

  56. Mouthon, L., Kaveri, S.V., Spalter, S.H., Lacroix-Desmazes, S., Lefranc, C, Desai, R., et al. (1996) Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin. Exp. Immunol. 104(Suppl. 1), 3–9.

    PubMed  CAS  Google Scholar 

  57. Ballow, M. (1997) Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. Allergy Clin. Immunol. 100, 151–157.

    CAS  Google Scholar 

  58. Shulman, S.R. and Bendet, M. (1997) Kawasaki disease. Compr. Ther. 23, 13–18.

    PubMed  CAS  Google Scholar 

  59. Sacher, R.A. and the IVIG Advisory Panel (2001) Intravenous immunoglobulin consensus statement. J. Allergy Clin. Immunol. 108, S139–S146.

    PubMed  CAS  Google Scholar 

  60. Leung, D.Y. (1996) Kawaski syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin. Exp. Immunol. 104(Suppl. 1), 49–54.

    PubMed  Google Scholar 

  61. Werdan, K. (2001) Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr. Opin. Crit. Care 7, 354–361.

    PubMed  CAS  Google Scholar 

  62. Alejandria, M.M., Lansang, M.A., Dans, L.F., and Mantaring, J.B.V. (2001) Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst. Rev. 2, CD001090.

    PubMed  Google Scholar 

  63. Erdem, G., Yurdakok, M., Tekinalp, G., and Ersoy, F. (1993) The use of IgM-enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants. Turk. J. Pediatr 35, 277–281.

    PubMed  CAS  Google Scholar 

  64. Weisman, L.E., Stoll, B.J., and Kueser, TJ. (1992) Intravenous immune globulin therapy for early onset sepsis in premature neonates. J. Pediatr. 121, 434–443.

    PubMed  CAS  Google Scholar 

  65. Chen, J.Y. (1996) Intravneous immunoglobulin in the treatment of full term and premature newborns with sepsis. J. Formos. Med. Assoc. 24, 733–742.

    Google Scholar 

  66. Haque, K.N., Zaidi, M.H., and Bahakim, H. (1988) IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am. J. Dis. Child. 142, 1293–1296.

    PubMed  CAS  Google Scholar 

  67. De Simone, C, Delogu, G., and Corbetta, G. (1988) Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Crit. Care Med. 16, 23–26.

    PubMed  Google Scholar 

  68. Schedel, I., Dreikhausen, U., Nentwig, B., Hockenschnieder, M., Rauthmann, D., Balikcioglu, S., et al. (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit. Care Med 19, 1004–1113.

    Google Scholar 

  69. Dominioni, L., Dionigi, R., Zanello, M., Chiaranda, M., Dionigi, R., Acquarolo, A., et al. (1991) Effect of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch. Surg. 126, 236–240.

    PubMed  CAS  Google Scholar 

  70. Grundmann, R. and Hornung, M. (1988) Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis—a prospective randomized study. Prog. Clin. Biol. Res. 272, 339–349.

    PubMed  CAS  Google Scholar 

  71. Wesloy, C, Kipping, N., and Grundmann, R. (1990) Immunoglobulin therapy of postoperative sepsis. Z. Exp. Chir. Transplant. Kunstliche Organe 23, 213–216.

    Google Scholar 

  72. Werdan, K., Pilz, G., and and the SBITS Study Group (1997) Polyvalent immune globulins (abstract). Shock 7(Suppl.), 5/1918.

    Google Scholar 

  73. Samuelsson, A., Towers, T.L., and Ravetch, J.V. (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484–486.

    PubMed  CAS  Google Scholar 

  74. Weisman, L.E., Cruess, D.F., and Fisher, G.W. (1994) Opsonic activity of commercially available standard intravenous immunoglobulin preparations. Pediatr. Infect. Dis. 13, 1122–1125.

    CAS  Google Scholar 

  75. Fisher, G.W., Cieslak, T.J., Wilson, S.R., Weisman, L.E., and Heeming, V.G. (1994) Opsonic antibodies to Staphylococcus epidermis: in vitro and in vivo studies using human intravenous immune globulin. J. Infect. Dis. 169, 324–329.

    Google Scholar 

  76. Yang, K.D., Bathras, J.M., Shigeoka, A.O., James, J., Pincus, S.H., and Hill, H.R. (1989) Mechanisms of bacterial opsonization by immune globulin intravenous: correlation of complement consumption with opsonic activity and protective efficacy. J. Infect. Dis. 159, 701–707.

    PubMed  CAS  Google Scholar 

  77. Hiemstra, P.S., Brands-Tajouiti, J., and van Furth, R. (1994) Comparison of antibody activity against various microorganisms in intravenous immunoglobulin preparations determined by ELISA and opsonic assay. J. Lab. Clin. Med. 123, 241–246.

    PubMed  CAS  Google Scholar 

  78. Patel, R., Rouse, M.S., Florez, M.V., Piper, K.E., Cockerill, F.R., Wilson, W.R. et al. (2000) Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. J. Infect. Dis. 181, 230–234.

    PubMed  CAS  Google Scholar 

  79. Norrby-Teglund, A., Kaul, R., Low, D.E., McGeer, A., Newton, D., et al. (1996) Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J. Immunol. 156, 3057–3064.

    PubMed  CAS  Google Scholar 

  80. Norrby-Teglund, A., Kaul, R., Low, D. E., McGeer, A., Andersson, J., Andersson, U., et al. (1996) Evidence for the presence of streptococcal superantigen neutralizing antibodies in normal polyspecific IgG (IVIG). Infect. Immun. 64, 5395–5398.

    PubMed  CAS  Google Scholar 

  81. Norrby-Teglund, A., Basma, H., Andersson, J., McGeer, A., Low, D. E., and Kotb, M. (1998) Varying titres of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G (IVIG): implications for therapeutic efficacy. Clin. Infect. Dis. 26, 631–638.

    PubMed  CAS  Google Scholar 

  82. Skansen-Saphir, U., Andersson, J., Bjbrk, L., and Andersson, U. (1994) Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur. J. Immunol. 24, 916–922.

    PubMed  CAS  Google Scholar 

  83. Lissner, R., Struff, W.G., Autenrieth, I.B., Woodcock, B.G., and Karch, H. (1999) Efficacy and potential clinical applications of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion. Eur. J. Surg. 584 (Suppl.), 17–25.

    Google Scholar 

  84. Stegmayr, B., Bjorck, S., Holm, S., Nisell, J., Rydvall, A., and Settergren, B. (1992) Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects. Scand. J. Infect. Dis. 24, 589–597.

    PubMed  CAS  Google Scholar 

  85. Darville, T., Milligan, L.B., and Laffoon, K.K. (1997) Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production. Infect. Immun. 65, 366–372.

    PubMed  CAS  Google Scholar 

  86. Takei, S., Arora, Y. K., and Walker, S. M. (1993) Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J. Clin. Invest. 91, 602–607.

    PubMed  CAS  Google Scholar 

  87. Norrby-Teglund, A., Ihendyane, N., Kansal, R., Basma, H., Kotb, M., Andersson, J., et al. (2000) Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens. Clin. Inf. Dis. 31, 1175–1182.

    CAS  Google Scholar 

  88. Arend, W.P., Smith, M.F.J., Janson, R.W., and Joslin, F.G. (1991) IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J. Immunol. 147, 1530–1536.

    PubMed  CAS  Google Scholar 

  89. Poutsiaka, D.D., Clark, B.D., Vannier, E., and Dinarello, C.A. (1991) Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood 78, 1275–1281.

    PubMed  CAS  Google Scholar 

  90. Ruiz de Souza, V., Carreno, M.P., Kaveri, S.V., Ledur, A., Sadeghi, H., Cavaillon, J.M., et al. (1995) Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur. J. Immunol. 25, 1267–1273.

    PubMed  CAS  Google Scholar 

  91. Andersson, U., Bjorck, L., Skansen-Saphir, U., and Andersson, J. (1994) Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol. Rev. 139, 21–43.

    PubMed  CAS  Google Scholar 

  92. Schalch, L., Rordorf-Adam, C, Dasch, J., and Jungi, T.W. (1991) IgG-stimulated and LPS-stimulated monocytes elaborate transforming growth factor type beta (TGF-beta) in active form. Biochem. Biophys. Res. Commun. 174, 885–891.

    PubMed  CAS  Google Scholar 

  93. Sasaki, H., Pollard, R.B., Schmitt, D., and Suzuki, F. (1992) Transforming growth factor-beta in the regulation of the immune response. Clin. Immunol. Immunopathol. 65, 1–9.

    PubMed  CAS  Google Scholar 

  94. Svenson, M., Hansen, M.B., and Bendtzen, K. (1993) Binding of cytokines to pharmaceutically prepared human immunoglobulin. J. Clin. Invest. 92, 2533–2539.

    PubMed  CAS  Google Scholar 

  95. Svenson, M., Hansen, M.B., Ross, C, Diamant, M., Rieneck, K., Nielsen, H., et al. (1998) Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91, 2054–2061.

    PubMed  CAS  Google Scholar 

  96. Wadhwa, M., Meager, A., Dilger, P., Bird, C, Dolman, C, Das, R.G., et al. (2000) Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1 alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Immunology 99, 113–123.

    PubMed  CAS  Google Scholar 

  97. Ross, C, Svenson, M., Hansen, M. B., Vejlsgaard, G. L. and Bendtzen, K. (1995) High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J. Clin. Invest. 95, 1974–1978.

    PubMed  CAS  Google Scholar 

  98. Grosse-Wilde, H., Blasczyk, R., and Westhoff, U. (1992) Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 39, 74–77.

    PubMed  CAS  Google Scholar 

  99. Lam, L., Whitsett, C. F., McNicholl, J. M., Hodge, T. W. and Hooper, J. (1993) Immunologically active proteins in intravenous immunoglobulin. Lancet 342, 678.

    PubMed  CAS  Google Scholar 

  100. Blasczyk, R., Westhoff, U., and Grosse-Wilde, H. (1993) Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341, 789–790.

    PubMed  CAS  Google Scholar 

  101. Andersson, J., Skansen-Saphir, U., Sparrelid, E., and Andersson, U. (1994) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin. Exp. Immunol. 104(Suppl.), 10–20.

    Google Scholar 

  102. Asano, T. and Ogawa, S. (2000) Expression of IL-8 in Kawasaki disease. Clin. Exp. Immunol. 122, 514–519.

    PubMed  CAS  Google Scholar 

  103. Nadal, D., Lauener, R.P., Braegger, C.P., Kaufhold, A., Simma, B., Lutticken, R. et al. (1993) T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J. Pediatr. 122, 727–729.

    PubMed  CAS  Google Scholar 

  104. Sharief, M.K., Ingram, D.A., Swash, M., and Thompson, E.J. (1999) IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 52, 1833–1838.

    PubMed  CAS  Google Scholar 

  105. Leung, D.Y., Cotran, R.S., Kurt-Jones, E., Burns, J.C., Newburger, J.W., and Pober, J.S. (1989) Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 2, 1298–1302.

    PubMed  CAS  Google Scholar 

  106. Haywood, C.T., McGeer, A., and Low, D.E. (1999) Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast. Reconstr. Surg. 103, 1567–1573.

    PubMed  CAS  Google Scholar 

  107. Cawley, M.J., Briggs, M., Haith, L.R.J., Reilly, K.J., Guilday, R.E., Braxton, G.R., et al. (1999) Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy 19, 1094–1098.

    PubMed  CAS  Google Scholar 

  108. Barry, W., Hudgins, L., Donta, S.T., and Pesanti, E.L. (1992) Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 267, 3315–3316.

    PubMed  CAS  Google Scholar 

  109. Chiu, C.H., Ou, J.T., Chang, K.S., and Lin, T.Y. (1997) Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics. Infection 25, 47–48.

    PubMed  CAS  Google Scholar 

  110. Lamothe, F., D’Amico, P., Ghosn, P., Tremblay, C, Braidy, J., and Patenaude, J. (1995) Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal disease: case report and review. J. Clin. Inf. Dis. 21, 1469–1470.

    CAS  Google Scholar 

  111. Mahieu, L.M., Holm, S.E., Goossens, H.J., and Van Acker, K.J. (1995) Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J. Pediatr. 127, 987–989.

    PubMed  CAS  Google Scholar 

  112. Perez, CM., Kubak, B.M., Cryer, H.G., Salemugodam, S., Vespa, P., and Farmer, D. (1997) Adjunctive treatment of streptococcal toxic shock syndrome with intravenous immunoglobulhr: case report and review. Am. J. Med. 102,111–113.

    PubMed  CAS  Google Scholar 

  113. Yong, J.M. (1994) Necrotising fasciitis. Lancet 343, 1427.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Anna Norrby-Teglund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald E. Low
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Malak Kotb
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Surgery and Molecular Sciences, VA Medical Center, University of Tennessee, Memphis, TN, USA

    Malak Kotb PhD

  2. Division of Infectious Diseases, Department of Internal Medicine, Centre Hospital Universitaire Vaudois, Lausanne, Switzerland

    Thierry Calandra MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Norrby-Teglund, A., Low, D.E., Kotb, M. (2003). Intravenous Immunoglobulin Adjunctive Therapy in Patients with Streptococcal Toxic Shock Syndrome and Necrotizing Fasciitis. In: Kotb, M., Calandra, T. (eds) Cytokines and Chemokines in Infectious Diseases Handbook. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-309-5_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-309-5_27

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-247-6

  • Online ISBN: 978-1-59259-309-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation